NovoCure
NVCR
197 hedge funds and large institutions have $4.17B invested in NovoCure in 2019 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 84 increasing their positions, 57 reducing their positions, and 31 closing their positions.
207% more call options, than puts
Call options by funds: $88.2M | Put options by funds: $28.7M
47% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 57
36% more capital invested
Capital invested by funds: $3.06B → $4.17B (+$1.11B)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
2.01% more ownership
Funds ownership: 66.92% → 68.93% (+2%)
6% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 31
2% less funds holding
Funds holding: 200 → 197 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$40M |
| 2 |
BlackRock
New York
|
+$38M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$24.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.3M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$14.7M |
| 2 |
DCP
Darsana Capital Partners
New York
|
-$12.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.85M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.81M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$6.8M |
NVCR Hedge Fund Activity: Q2 2019 in Review
197 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q2 2019, worth a combined $4.17B — up 36% from $3.06B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new NVCR positions and 31 closed out — a net gain of 2 holders — while 84 added to existing stakes and 57 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $40M. The largest seller was Westfield Capital Management, exiting entirely with an estimated $14.7M sold.
- 197 institutional investors held NovoCure (NVCR) as of Q2 2019, down from 200 in Q1 2019.
- Funds reported $4.17B of NovoCure stock for Q2 2019, up 36% quarter-over-quarter.
- 33 funds opened new NovoCure positions in Q2 2019 and 31 closed out, a net change of +2 holders.
- The largest NovoCure buyer in Q2 2019 was Baillie Gifford & Co, an estimated $40M added.
- The largest NovoCure seller in Q2 2019 was Westfield Capital Management, an estimated $14.7M sold.
Based on aggregated 13F filings for Q2 2019.